Articles tagged with Pertussis
A recent study found that rates of infant immunization with pertussis-containing vaccine did not increase during a pertussis epidemic in Washington state. Despite high risk, vaccination rates remained stable before and during the epidemic, suggesting that conventional wisdom about vaccine acceptance may be challenged.
The study found no significant increase in adverse events for mothers or infants who received the Tdap vaccine during pregnancy. Infants born to vaccinated mothers had higher concentrations of pertussis antibodies, a key finding that could help prevent infant pertussis.
A comprehensive genomic analysis of Bordetella pertussis bacteria reveals the impact of vaccination on its spread and diversification. The study shows that vaccination has dramatically reduced rates of infection and loss of life from whooping cough, but strategies used to date have not completely eradicated strains of the bacteria.
A UNSW-led study found that 80% of 2012 Australian whooping cough cases were caused by pertactin-free strains, which may evade vaccine antibodies. The shift could reduce the vaccine's effectiveness in Australia.
A study found that changing hospital orders increased pertussis immunization rates by 69% among new mothers, providing protection for themselves and their newborns. Implementing a standing order led to the largest increase in vaccinations, raising the rate from zero to 69%.
A new intranasal vaccine against pertussis has been successfully tested in humans, inducing an immune response that lasted for at least 6 months. The vaccine was found to be safe and effective, with no adverse events reported even at the high dose.
The pertactin antigen, crucial to the effectiveness of the whooping cough vaccine, is now absent from more than half of US bacterial isolates. The absence of this antigen has significant implications for public health authorities and highlights the need to monitor circulating bacterial populations.
A new study published in Pediatrics found that widespread vaccination of adolescents for pertussis was linked to a modest reduction in infant hospitalizations. The research suggests increasing vaccination rates among teens and adults is crucial to stem the ongoing pertussis epidemic among infants.
A study by Jason M. Glanz and colleagues found that undervaccination with the DTaP vaccine increases the risk of pertussis in children aged 3-36 months. The research involved 72 cases of pertussis and 288 controls, showing that undervaccinated children were 18.56 times more likely to contract the disease than their vaccinated peers.
A University of Michigan-led study challenges prevailing theories on whooping cough's resurgence by showing vaccines offer long-lived protection and reduced transmission. The study highlights the success of Thailand's childhood immunization program in reducing pertussis cases, especially among infants.
A new Kaiser Permanente study published in Pediatrics found that whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak in California. The study examined 138 individuals with confirmed pertussis and found that teenagers vaccinated with four dose...
A study found that infants with more severe pertussis have higher white blood cell counts and are at higher risk of death. Infants with less severe disease had lower white blood cell counts and were less likely to experience complications.
A new study found that the tetanus-diphtheria-acellular pertussis (Tdap) vaccine is safe for seniors, with minor injection site reactions being the most common adverse event. The study's findings support the recommendation that older adults receive the vaccine to protect themselves and others from pertussis.
A Kaiser Permanente study found that Tdap vaccination is as safe as Td vaccination for adults 65 and older, with no increased risk of injection site reactions. The study provides empirical evidence supporting the use of Tdap in reducing pertussis infections among older adults.
A study in California found that children with pertussis had lower odds of having received all 5 doses of the DTaP vaccine series. The risk increased as the time since last vaccination lengthened, indicating a progressive decrease in estimated vaccine effectiveness each year after the final dose.
A study found that protection against whooping cough decreases by more than 40% each year after the fifth dose of DTaP vaccine. The decline in protection depends on the initial effectiveness of the fifth dose, with lower effectiveness leading to reduced protection.
A 2010 California whooping cough epidemic highlighted the importance of vaccination for adults, pregnant women, and infant contacts. The disease had the highest incidence in infants under 6 months, with Hispanics being most affected in this age group, while Whites were most affected among children and adolescents.
A new model based on game theory and social learning can predict the patterns of vaccine scares, explaining why vaccine uptake takes time to recover after a scare. The model highlights the interplay between disease dynamics and vaccination behavior, suggesting that herd immunity can lead to complacency among unvaccinated individuals.
A new genotype of the Bordetella pertussis bacterium has been identified as responsible for a sharp rise in whooping cough cases in Australia. The strain is believed to be evading the current acellular vaccine's protective effects, leading to an increase in life-threatening respiratory illness.
Researchers used a novel technique to count disease-spreading events in a high school population of 788 volunteers. They found that most people had a fairly high number of person-to-person interactions, but there were no super-spreaders who stood out from the rest.
A University of Michigan study found that contact patterns among different age groups can explain the observed shifts in whooping cough prevalence and incidence. The research suggests that blanket booster-vaccination programs for adults may not be an efficient strategy for controlling the disease.
Analyses of serological and social contact data reveal that childhood vaccination against pertussis has led to a shift in the disease's burden, with adolescents and adults becoming reservoirs for asymptomatic infection. The study suggests that life-long protection through a vaccine could potentially eliminate pertussis.
Researchers at Duke University Medical Center found a successful pilot program increasing HPV vaccination rates from 0 to 44% among post-partum women. The study suggests that OB/GYN clinics can play a key role in vaccinating eligible adults, particularly pregnant and post-partum women.
A new study published in PLOS Pathogens found that whooping cough immunity typically lasts at least 30 years and perhaps as long as 70 years after natural infection. The research suggests that repeat infections contribute relatively little to transmission and may even boost immunity in individuals with waning protection.
A recent study by Kaiser Permanente found that unvaccinated children are significantly more likely to contract pertussis, also known as whooping cough. The research used electronic health records to analyze the risk of vaccine refusal and its impact on pertussis infections.
The study found that global child immunization coverage is significantly lower than reported by individual nations or WHO/UNICEF estimates. The researchers estimated the coverage of three doses of diphtheria, tetanus, and whooping cough vaccine (DPT3) based on surveys using all available data from 193 countries between 1986-2006.
A new study finds that accelerating the pertussis vaccine schedule by two weeks could prevent at least 1,236 cases of the disease each year. This shift would also reduce hospitalizations and deaths attributed to pertussis, a disease that can be life-threatening in young infants.
The US FDA has approved KINRIX, a combination vaccine that protects against four serious diseases: diphtheria, tetanus, pertussis and polio. Clinical studies show similar protection to separately administered vaccines with a comparable safety profile.
A study analyzing Saskatchewan's pertussis incidence between 1995-2005 found lower rates among children with whole-cell pertussis or a combination of whole-cell and acellular pertussis vaccines. The findings contradict recent reports, suggesting reconsidering the optimal immunization strategy against pertussis.
States with personal belief exemptions and easily accessible immunization exemptions experience higher rates of whooping cough, according to a study published in JAMA. The study found that states granting personal belief exemptions had higher exemption rates, leading to increased incidence of pertussis.
The incidence of pertussis has increased in Canada, particularly among young infants, adolescents, and adults. Authorities have recommended booster doses for adolescents since 2004 to combat the disease.
Research reveals that pertussis toxin is responsible for prolonging the infection period in immune and vaccinated hosts. The study found that antibodies produced by vaccines are effective only seven days after administration, allowing the bacteria to grow and spread before the body can mount an effective response.
A study using mouse models found that B. pertussis toxin inhibits neutrophil recruitment, delaying antibody-mediated clearance and allowing repeated infection. Another study identified thrombospondin-1 as a novel mediator of ischemic damage in the kidney, which may be a target for drugs to reduce kidney failure risk.
A recent study published in the New England Journal of Medicine found that an estimated one in 300 adolescents and adults contracts pertussis each year. The study's results demonstrated that a new pertussis vaccine is over 90% effective in preventing the illness, making it a strongly encouraged booster shot for adults.
A 2.5-year study involving 2,781 individuals aged 15-65 found the acellular pertussis vaccine to be safe and 92% effective in preventing the disease among adults and adolescents. The vaccine's effectiveness could help reduce transmission of the disease.
A recent study suggests that a one-time adolescent vaccination against whooping cough could prevent 36% of projected cases while being reasonably cost-effective. The analysis considered various vaccination strategies and their impact on disease incidence, vaccine efficacy, side effects, and costs.
A recent study published in JAMA Network found that the Tdap vaccine elicited robust immune responses in adolescents and adults to pertussis, tetanus, and diphtheria antigens. The potential benefits of widespread use of an adolescent and adult pertussis booster vaccine include a reduction in pertussis disease.
A new combination vaccine for diphtheria, tetanus, and pertussis has been found to be effective in providing immunity against whooping cough, with minimal adverse reactions. The vaccine is composed of four protein fragments from the pertussis bacterium and is comparable to existing vaccines in terms of immune response and safety.
Boostrix is approved by the FDA for use in US adolescents against pertussis, with reported cases rising nearly 20-fold since 1976. Experts estimate the true incidence of the disease may be greater than one million cases per year, particularly among teens.
The Society for Adolescent Medicine advocates for adolescents to receive extended protection against pertussis. Adding a pertussis component to the current tetanus-diphtheria booster vaccine could help prevent this disease in teens and reduce transmission to infants.
The FDA Advisory Committee has unanimously recommended approval of Boostrix, a vaccine candidate against pertussis, for use in adolescents. The vaccine showed comparable safety and immunogenicity to a U.S.-licensed Td vaccine, with higher anti-pertussis antibody levels in adolescents than in infants.
The Global Pertussis Initiative recommends introducing universal adolescent vaccination programs and vaccinating certain target groups to enhance immunity. Adolescents are at risk of contracting whooping cough if they don't receive booster shots, making them a key population for vaccination.
A new pertussis booster vaccine candidate has shown promising results in a clinical trial, providing extended protection against whooping cough, diphtheria, and tetanus for adolescents. The vaccine, Boostrix, demonstrated high levels of anti-pertussis antibodies and comparable side effects to the existing Td vaccine.
The study found that nonspecific clinical diagnosis, unreliable testing methods, and communication issues hindered effective diagnosis of pertussis during the outbreak. Despite these challenges, the epidemic was successfully managed without deaths reported.
The incidence of pertussis among infants increased significantly between 1980 and 1999, with a 49% rise in reported cases. The majority of these cases occurred among infants under four months old, suggesting the need for improved vaccination strategies to control the spread of the disease.
Researchers at UT Southwestern and Children's will develop protocols and procedures for a thermocycler called GeneXpert, which rapidly processes and analyzes DNA samples. The new testing methods should allow children to leave the hospital sooner or avoid hospitalization altogether, with results available within hours.
A new study reveals that media reports of vaccine injuries can cause fear, lead to costly litigation, and prevent infants from being immunized. The authors urge journalists to report on rare adverse events without distorting the facts, highlighting the importance of accurate information in protecting public health.